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1. Introduction 
A critical role of the subthalamic nucleus (STN) in the control of movement has been 
proposed based on the observations that its lesion or high-frequency stimulation, aimed at 
altering its activity, is effective in alleviating clinical features of Parkinson’s disease 
(Bergman et al,. 1990; Bennazouz et al., 1993; Pollak et al., 1993, Benazzouz et al., 2000). 
Indeed, overactivity of the subthalamic neurons due to the loss of midbrain dopaminergic 
neurons is believed to be a key feature in Parkinson’s disease.  Several studies indicate that 
the activity of STN neurons can be influenced directly by dopamine and its receptor 
agonists/antagonists. Indeed, the STN receives a direct dopaminergic input arising in the 
substantia nigra pars compacta (SNc) and both dopamine D1- and D2-like receptors are 
present in the STN (Canteras et al., 1990; Hassani et al., 1997; Flores et al., 1999). 
Understanding the position of the STN within the basal ganglia and the possible direct 
effects of dopamine and its ligands at the level of this nucleus in normal and parkinsonian 
states may be important in the development of new therapies for Parkinson’s disease. The 
purpose of this chapter is to give an overview of the current position of the STN in the basal 
ganglia motorloop and to clarify the role of dopamine at the level of the STN in both normal 
conditions and in parkinsonian experimental animal models. 
2. The subthalamic nucleus and its connections 
Despite the small size of this biconvex-shaped structure, the STN has an important role in 
the modulation of the basal ganglia output and thus movement control (DeLong & 
Wichmann, 2007; Obeso et al., 2008; Gubbelini et al., 2009). Indeed, together with the 
striatum, the STN forms the major input to the basal ganglia and is considered an important 
relay nucleus of the indirect pathway. In this section, the role of the STN within the basal 
ganglia and its connections are described. 
2.1 The subthalamic nucleus as a part of the basal ganglia 
The basal ganglia consist of five interconnected nuclei including the caudate nucleus, the 
putamen [which forms together with the caudate nucleus the striatum], the globus pallidus 
(pars interna (GPi) and externa (GPe)) the SN (SNc and substantia nigra pars reticulata (SNr)) 
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and the STN (DeLong, 1990; Blandini et al., 2000). Albin and DeLong proposed a schematic 
view of the basal ganglia organisation which has been used for many years as a reference for 
understanding their functioning in physiological and pathological conditions (Albin et al., 
1989; DeLong, 1990; Gubellini et al., 2009). Currently, this view has been replaced by a more 
recent representation of the organisation of the basal ganglia based on novel anatomical, 
neurochemical and physiological data (Levy et al., 1997; Gubellini et al., 2009). In this 
representation, the striatum and STN are considered as the two major input structures of the 
basal ganglia. Both nuclei receive input from the cerebral cortex, whereas the GPi and SNr 
provide output of the basal ganglia to the thalamus and brainstem (DeLong & Wichmann, 
2007; Obeso et al., 2008). The striatum is connected with these output structures via a 
monosynaptic direct pathway and a polysynaptic indirect pathway which includes the GPe 
and the STN. The striatal direct pathway neurons also receive input from the intralaminar 
nuclei of the thalamus. The STN is directly connected with the output nuclei. 
Besides motor functions, the basal ganglia are involved in cognition and emotion 
(Alexander et al., 1990; Smith et al., 1998). Indeed, the basal ganglia can be functionally 
divided into different cortico-subcortical circuits: the motor loop, the associative loop and 
the limbic loop. Each circuit originates from individual cortical areas, innervates the 
respective regions of the striatum, GP and SN and, via the thalamus,  terminates in their 
respective cortical areas of origin (Hamani et al., 2004; DeLong & Wichmann, 2007). Like the 
other structures of the basal ganglia, the STN is subdivided into different major parts: a 
motor, an associative and a limbic part (Hamani et al., 2004; Benarroch, 2008). The motor 
part is represented by the large dorsolateral portion of the STN whereas the associative and 
the limbic part are represented by respectively the ventromedial portion and the medial tip 
of the STN. Currently, the best characterized cortico-subcortical circuit is the motor circuit. 
The motor loop (figure 1) originates from the motor cortex and sends glutamatergic 
projections to both input nuclei, the striatum and the STN (DeLong & Wichmann, 2007; 
Obeso et al., 2008). Striatal efferent neurons are γ-aminobutyric acid (GABA)-ergic and are 
connected, as mentioned before, with the output nuclei, GPi and SNr, by the direct or the 
indirect pathway. Neurons from the direct pathway, which bear dopamine D1 receptors 
(excitatory receptors), project directly to the output nuclei. Neurons from the indirect 
pathway express dopamine D2 receptors (inhibitory receptors) and send GABA-ergic 
projections to the GPe. The GPe in turn influences the STN by GABA-ergic projections. The 
STN, which is a glutamatergic structure, provides excitatory input to the output nuclei of 
the basal ganglia. The balance within the basal ganglia is regulated by the dopaminergic 
neurons from the SNc. Release of dopamine in the striatum leads to an increase in activity of 
the direct pathway via the D1 receptors, whereas the activity of the indirect pathway is 
decreased via the D2 receptors. This dopamine release results in a reduction in the activity 
of the output nuclei and thus facilitates movement. In Parkinson’s disease, nigrostriatal 
degeneration leads to hyperactivity of the STN and thus to an increase of the output nuclei 
activity which in turn results in inhibition of ongoing movement. 
2.2 Subthalamic nucleus afferents and efferents 
As described above, the STN has a pivotal position in the motor circuitry. Indeed, it is part 
of a complex organisation within the basal ganglia and is connected with a wide range of 
structures. It is the only glutamatergic nucleus of the basal ganglia (Smith & Parent, 1988; 
Blandini et al., 2000; Hamani et al., 2004). The STN provides a strong excitatory input to the 
two output structures, GPi and SNr, but also to the GPe. Via its excitatory input to the SNc, 
it influences the regulation of the dopamine release (Smith et al., 1990; Parent & Hazrati, 
1995; Hamani et al., 2004). Besides the main efferent projections described above, the STN is 
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connected with the peduncolopontine nucleus and the ventral tegmental area through 
which it influences the processing of emotional information (Smith et al., 1990; Parent & 
Hazrati, 1995; Haegelen et al., 2009). Furthermore, the STN sends poor glutamatergic 
projections to the striatum and the motor cortex (Smith et al., 1990; Blandini et al., 2000). 
 
 
Fig. 1. Left brain hemisphere: motor loop in a normal condition. Right brain hemisphere: 
motor loop in Parkinson’s disease. The motor loop originates from the motor cortex and 
sends glutamatergic projections to both input nuclei, the striatum and the STN. Striatal 
neurons from the direct pathway (contain D1 receptors) project directly to the output nuclei 
whereas neurons from the indirect pathway (contain D2 receptors) send GABA-ergic 
projections to the GPe. The GPe in turn influences the STN by GABA-ergic projections. The 
STN provides excitatory input to the output nuclei. Release of dopamine in the striatum 
leads to an increase in activity of the direct pathway via the D1 receptors whereas the 
activity of the indirect pathway is decreased via the D2 receptors. Dopamine release results 
in a reduction in the activity of the output nuclei and, via the thalamus, leads to 
glutamatergic projections to the cortex which facilitates movement. In Parkinson’s disease, 
dopaminergic degeneration of the SNc leads to hyperactivity of the STN and thus an 
increase of the output nuclei activity which in turn results in inhibition of ongoing 
movement. The thickness of the depicted projections reflects their activity. 
Neurons of the STN receive two major projections: a direct excitatory glutamatergic input 
from the cerebral cortex and an important inhibitory GABA-ergic innervation from the GPe 
(Blandini et al., 2000; Hamani et al., 2004; DeLong & Wichmann, 2007). It also receives 
inhibitory projections from the GPi, SNr and striatum. Another source of excitatory input to 
the STN is the centromedian-parafascicular nucleus of the thalamus. Furthermore, 
glutamatergic and cholinergic projections arise from the pedunculopontine nucleus to the 
STN. Besides the main glutamatergic and GABA-ergic afferents to the STN, dopaminergic 
neurons from the SNc also innervate the STN (Campbell et al., 1985; Canteras et al., 1990; 
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Hassani et al., 1996). These neurons modulate the activity of glutamatergic and GABA-ergic 
afferents arising from respectively the cortex and the pallidum to the STN. In addition, the 
STN receives serotonergic projections from the dorsal raphe nucleus which may also be 
involved in the modulation of the STN activity (Blandini et al., 2000; Hamani et al., 2004; 
DeLong & Wichmann, 2007). In this chapter, the importance of the dopaminergic input from 
the SNc to the STN will be described. 
3. Dopamine receptors in the subthalamic nucleus 
Because of their relevance in Parkinson’s disease, large research efforts have been made to 
investigate the presence and localisation of dopamine receptors in the central nervous 
system, especially since the mid to late eighties (Wamsley et al., 1989). These receptors 
consist of a large family of D1-like dopamine receptors, divided into D1 and D5 receptors, 
and D2-like dopamine receptors, divided into D2, D3 and D4 receptors (Niznik, 1987; 
Niznik et al., 1992; Sibley et al., 1992; Gingrich et al., 1993). In general, D1 receptors are 
known to be positively coupled to adenylatecyclase via a Gs protein, whereas D2 receptors 
are either uncoupled or negatively coupled to adenylatecyclase (Onali et al., 1985; Memo et 
al., 1986). Both the D1-like and the D2-like dopamine receptors are known to be abundantly 
expressed and widely distributed throughout different basal ganglia nuclei. A series of 
experimental studies indicate that functional dopamine receptors are expressed and 
localised in the STN but there is still debate concerning the receptor subtypes.  
The occurance of D1 receptors in the STN has been reported in a number of histological 
studies (Brown et al., 1979; Dubois et al., 1986; Fremeau et al., 1991; Mansour et al., 1992). 
However, Johnson et al. reported that D1 receptors are not located within the borders of the 
STN but are situated in the cerebral peduncles (Johnson et al., 1994). By means of 
autoradiography in rats, Kreiss et al. confirmed the presence of D1 dopamine receptors along 
the ventral edge of the STN which borders the cerebral peduncle. This was confirmed in a 
morphological study showing that the dendrites of STN neurons extend across the ventral 
STN borders into the peduncles (Kita et al., 1983). D1 receptors were not observed in the dorsal 
regions of the STN (Kreiss et al., 1996). Another autoradiographic study confirmed the 
presence of D1 receptors in the STN and found that there was a clear dorsoventral gradient in 
D1 binding sites at the level of the STN (Flores et al., 1999). Dopamine D2 receptors have also 
been shown to be present at the level of the rat STN by several groups (Boyson et al., 1986; 
Bouthenet et al., 1987; Johnson et al., 1994). Flores et al. were able to show the presence of all 
three subtypes of the D2-like receptors, although the amounts of D3 dopamine receptors were 
very low (Flores et al., 1999). However, no dopamine D1, D2, D3 nor D4 mRNA was detected 
by several investigators in both rat and human STN (Fremeau et al., 1991; Mansour et al., 1992; 
Augood et al., 2000). Nevertheless, Bouthenet et al. showed the presence of both D2 and D3 
mRNA at the level of the STN with in situ histochemistry (Bouthenet et al., 1991). Moreover, 
using reverse transcriptase polymerase chain reaction the presence of D1 receptor mRNA was 
confirmed (Flores et al., 1999), together with the expression of the mRNA encoding for D2 and 
D3 receptors. By means of in situ hybridisation, high levels of D5 dopamine receptor mRNA 
were found at the level of the STN (Svenningson & Le Moine, 2002). However, they were 
unable to detect mRNA levels for all other dopamine receptor subtypes. Baufreton et al. also 
showed the presence of D5 dopamine receptors on burst competent STN neurons with single-
cell reverse transcription-PCR profiling. They also used an antibody raised against a peptide 
sequence of cloned D5 receptor and detected immunoreactivity in the STN cell bodies 
(Baufreton et al., 2003). 
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Thus, using an array of techniques, all dopamine receptor subtypes have been detected in 
STN. However, the data remain inconsistent and more research is warranted. 
4. Role of dopamine at the level of the subthalamic nucleus 
Numerous studies in the past have suggested a direct role of dopamine and its receptor 
ligands at the level of the STN. As described above, the presence of both D1- and D2-like 
dopamine receptors in the STN has been demonstrated. Several anatomical studies provided 
evidence for a direct and substantial nigrosubthalamic dopaminergic projection in rats 
(Campbell et al., 1985; Canteras et al., 1990; Hassani et al., 1996). Moreover, we and others 
have shown that dopamine is released within the STN in vivo (Cragg et al., 2004; Ampe et 
al., 2007). However, despite numerous investigations, many discrepancies still exist with 
regard to the effect of dopamine and its receptor agonists on the activity of STN neurons. In 
the classical model of the basal ganglia motorloop, dopamine is widely assumed to exert an 
inhibitory influence on STN neuronal activity (Albin et al., 1995) and dopamine should 
reduce excitability of STN neurons in parkinsonian brain (DeLong, 1990; Bergman et al., 
1994).  A variety of in vitro an in vivo experimental studies have addressed this issue.   
Several in vitro electrophysiological studies have shown inhibitory effects of dopamine on 
STN neuronal activity (Campbell et al., 1985; Hassani et al., 1999). However, others have 
found dopaminergic agonists to excite the activity of STN neurons.  Indeed, Zhu et al. 
(2002a) showed that a dopamine bath application significantly increased the firing rates of 
STN neurons in a concentration-dependent fashion in both intact and 6-hydroxydopamine 
(6-OHDA) lesioned rats. They also showed that this excitatory effect of dopamine was 
largely mimicked by application of the dopamine D2 receptor agonist quinpirole.  The 
dopamine D1 receptor agonist SKF-38393 showed a trend towards an increase in STN firing 
rate, but this effect was only significant in the 6-OHDA lesioned group. They concluded that 
dopamine exerts an excitatory influence on STN neuronal activity and that this effect is 
likely to be established by stimulation of D2 receptors. They also observed that dopamine, in 
6-OHDA lesioned rats, in addition to the firing rates, also changes the irregular firing 
pattern into a more regular pacemaker pattern at the level of the STN (Zhu et al., 2002a). The 
same group also demonstrated that dopamine increases the firing rates of action potentials 
and produces inward currents in STN neurons. Together with the fact that these inward 
currents persisted when excitatory synaptic transmission was blocked, illustrated that 
dopamine exerted a direct excitatory effect at the level of the STN (Zhu et al., 2002b). In 
another in vitro electrophysiological study, Tofighy et al. (2003) showed that dopamine 
caused modest, but reliable, increases in the firing rates of STN neurons and considered this 
effect likely to be a direct excitatory action on STN neurons.  The dopamine D2 receptor 
agonists quinpirole and bromocriptine caused concentration-dependent increases in the 
firing rates of STN neurons, whereas the mixed dopamine D1/D2 receptor agonist 
apomorphine caused only weak and less reproducible responses in STN firing rates. The 
dopamine D1 receptor agonist, SKF 38393 was without effect on STN firing rates. These 
results initially suggested an excitatory effect of dopamine on the STN neurons through a 
direct D2 receptor mediated mechanism. However, due to the fact that the effective 
concentration of all agonists was high, the authors stated that the effects could well be non-
specific. This, together with the inconsistent effects of apomorphine and the inability of 
dopamine D2 (nor D1) receptor antagonists to reduce the observed excitatory effects led the 
authors to conclude that these effects probably cannot be assigned to dopamine receptors 
but to non-catecholaminergic receptors (Tofighy et al., 2003).  Baufreton et al., by means of 
in vitro electrophysiological recordings, showed that activating D1 and D2 dopamine 
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receptors with D1 and D2 agonists promotes pace making at the level of the STN by 
increasing the firing frequency of neurons that exhibit tonic firing capacity and by changing 
firing in burst-competent and spontaneously burst-firing neurons. Moreover, they also 
showed that D5 dopamine receptors may potentiate burst-firing in STN neurons by 
modulating L-type calcium channels in the absence of dopamine (Baufreton et al., 2003; 
Baufreton et al., 2005). Finally, Loucif et al. showed that dopamine clearly produces 
subthalamic membrane depolarisation leading towards an increase in firing rate. This effect 
seemed to be due to action on D1-like dopamine receptor mediated activation of a cyclic-
nucleotide gated non-specific cation conductance. This conductance also contributed to the 
membrane depolarisation changing STN neuronal bursting towards a regular activity 
(Loucif et al., 2008). Thus, in vitro studies suggest that dopamine at the level of the STN 
exerts excitatory effects, possibly via D2 receptors. More recent studies, however, suggest 
D1-like mediated effects. 
Several in vivo studies showed an inhibitory effect of dopamine on the activity of STN 
neurons. Campbell et al., using horseradish peroxidase and microiontophoresis, suggested 
that dopamine suppresses STN activity (Campbell et al., 1985). Injection of the mixed D1/D2 
agonist apomorphine into the STN of intact rats decreased the mean firing rates of STN 
neurons significantly. However, an increase of firing rates was observed in 6-OHDA lesioned 
rats (Hassani et al., 1999). The selective D1 dopamine receptor agonist SKF 82958, when 
injected into the STN, decreased the activity of STN neurons in both intact and 6-OHDA 
lesioned rats. Injection of the selective D2 dopamine receptor agonist quinpirole decreased the 
firing rate of STN neurons, whereas in 6-OHDA lesioned animals it significantly increased 
firing rates. Hassani and colleagues concluded that dopamine receptor agonists probably have 
an inhibitory effect on STN neurons of intact rats via a D1 dopamine receptor mediated 
mechanism, whereas in 6-OHDA lesioned animals dopamine receptor agonists stimulate the 
STN via D2 dopamine receptors and inhibit activity via D1 dopamine receptors (Hassani et al., 
1999). On the other hand, several other in vivo studies suggested a facilitatory effect of 
dopamine at the level of the STN. Glucose utilization was decreased in the STN following 
systemic administration of the dopamine D1 receptor antagonist SCH23390 (Trugman et al., 
1993) whereas it was increased following systemic administration of the mixed D1/D2 
dopamine receptor agonist apomorphine or following  amphetamine (Brown et al., 1978; 
Wechsler et al., 1979; Trugman et al., 1993). Kreiss et al. described predominantly D1 mediated 
excitatory effects since neuronal firing rates in the STN of intact rats was increased following a 
systemic administration of apomorphine. Systemic administration of the dopamine D2 
receptor agonist quinpirole did not alter STN firing rates, whereas the dopamine D1 receptor 
agonists SKF 38393 and SKF 82958 clearly increased STN firing rates. Local administration of 
the dopamine D1 receptor agonist SKF 82958 also increased firing rates (Kreiss et al, 1996). 
Using microiontophoresis, a clear excitatory effect of dopamine on the majority of STN 
neurons in both intact and 6-OHDA lesioned rats was observed (Ni et al., 2001). The excitatory 
effect of dopamine in the 6-OHDA lesioned rats was similar to that in intact rats. Their results 
were in good agreement with previous studies using the same technique also showing that 
dopamine induced an increase in firing rate of almost all STN neurons of intact rats (Mintz et 
al, 1986). Selective dopamine depletion by injection of 6-OHDA in the STN resulted in a clear 
decrease of the firing rate together with a change in firing pattern, reinforcing the evidence of 
an excitatory effect of dopamine at the level of the STN (Ni et al. 2001).  Finally, we were the 
first to study the in vivo release of dopamine and glutamate in the STN using in vivo 
microdialysis (Ampe et al., 2007). We were able to establish that perfusion of the STN with 
NMDA enhanced dopamine and glutamate release in a concentration dependent manner. We 
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showed that this release was dependent on both D1 and D2 receptors since the NMDA-
mediated effects were blocked by local perfusion of both the dopamine D1 receptor antagonist 
SCH 23390 and the dopamine D2 receptor antagonist raclopride, confirming the presence of 
this type of receptors in the STN.  The importance of the dopaminergic innervation to the STN 
in these effects was demonstrated by the fact that depletion of dopamine by 6-OHDA lesioning 
of the SNc resulted in an absence of the effects of NMDA in the STN (Ampe et al., 2007). More 
recently, we showed that perfusion of the STN with dopamine or its D1 receptor agonist 
SKF38393 results in excitation of the STN since extracellular glutamate is increased. Again, 6-
OHDA lesioning abolished these effects (Ampe et al., submitted elsewhere). Taken together, 
the majority of the available in vivo data clearly suggest an excitatory effect of dopamine on 
STN neurons that is mediated via dopamine D1 receptors.  
 
  Intact    6-OHDA   
  STN inhibition STN activation STN inhibition STN activation 
In Vitro DA 
Campbell et al., 1985
Hassani et al., 1999 
 
DA 
Zhu et al., 2002a 
Zhu et al., 2002b 
D2 - quinpirole 
Zhu et al., 2002a 
Tofighy et al., 2003 
D1/D5- 
SKF82958;SKF 
81297 
Baufreton et al., 2003
 DA 
Zhu et al., 2002b 
D2 - quinpirole 
Zhu et al., 2002a 
Baufreton et al., 
2005 
D1/D5- 
SKF38393 ; 
SKF82958; 
SKF 81297 
Baufreton et al., 
2005 
Loucif et al, 2008 
In Vivo DA 
Campbell et al., 1985
amphetamine 
Welchsler et al.,1979
D1/D2 - 
apomorphine 
Brown et al., 1978 
Hassani et al., 1999 
D1/D5 – SKF82958
Hassani et al., 1999 
D2 - quinpirole 
Hassani et al., 1999
DA 
Mintz et al., 1986 
Ni et al., 2001 
D1/D2 - 
apomorphine 
Trugmann et al.,1993
Kreiss et al., 1996 
D1/D5-SKF38393 ; 
SKF82958 
Ni et al., 2001 
Kreiss et al., 1996 
 
D1/D5 – SKF82958
Hassani et al., 1999
DA 
Ni et al., 2001 
D2 - quinpirole 
Hassani et al., 1999 
Ni et al., 2001 
D1/D5-SKF38393 
Ni et al., 2001 
 
Table 1. Overview of different publications regarding the effects of dopamine and its 
agonists on subthalamic activity in both intact and 6-OHDA lesioned rats.   
5. Implications for Parkinson’s disease treatment strategies 
The existence of a direct nigrosubthalamic dopaminergic pathway is nowadays a well 
established fact. Moreover, dopamine receptors of both D1 and D2 like families have been 
shown to be present at the level of the STN. Otheiatal level, it is now clear that dopamine 
exerts direct effects at the level of other basal ganglia nuclei of which the STN plays a 
pivotal role in Parkinson’s disease. Since altered neuronal output from the STN plays a 
central role in the pathophysiology of Parkinson’s disease and overactivity of subthalamic 
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neurons due to the loss of dopaminergic neurons contributes to increased excitation of the 
main output nuclei, effects of dopaminergic drugs (still the main drug treatment for 
Parkinson’s disease) on subthalamic neuronal activity is highly important. It has been 
shown in different studies that dopamine and its agonists can alter subthalamic activity in 
both intact and parkinsonian animals. However, discrepancies still exist regarding the 
effects of dopaminergic stimulation.  In the pathological state, most in vitro and in vivo 
studies agree on an excitatory effect of dopamine at the subthalamic level. Surprisingly, this 
opposes the current hypothesis that dopamine receptor stimulation alleviates symptoms of 
Parkinson’s disease by reducing STN output (DeLong, 1990). The receptor subtypes by 
which dopamine exerts these excitatory effects differ between studies and different effects 
are seen depending on the receptor subtype. Moreover, not only effects on firing rates but 
also effects on subthalamic firing patterns were seen after dopamine application, further 
strengthening the hypothesis that dopamine clearly alters neuronal output at the 
subthalamic level. Dopamine replacement therapy remains the standard therapy for 
Parkinson’s disease. Most of the dopamine agonists used to treat the symptoms of 
Parkinson’s disease are non-specific for one or the other receptor subtype. We also know 
that after the so-called "honeymoon period" the effective response to dopamine wears off, 
and that undesirable side effects, like dyskinesia, occur. Further investigation towards an 
even better understanding of the effects of dopamine at the subthalamic level, and the 
receptor subtypes involved in these effects, can lead towards the development of better 
targeted drugs for the treatment of Parkinson’s disease. Therefore, future studies 
investigating the effects of selective ligands of different dopamine receptor subtypes in 
experimental Parkinson’s disease models, combining investigation towards 
electrophysiological effects and effects on neurotransmitter release of these ligands at the 
level of the STN, are necessary for developing more specific and selective drugs to treat 
different stages of Parkinson’s disease. 
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